title: Clinicopathological features and outcome of hepatic resection for liver metastasis from gastric cancer.
abstract: OBJECTIVE
  The efficacy of operative resection of lesions metastatic to the liver from colorectal or neuroendocrine tumor is well established. However, the appropriate management of liver metastasis from gastric cancer is controversial. We analyzed the prognostic factors in patients who underwent hepatectomy for metastasis from gastric cancer.
  
  
  METHODS
  Retrospective clinical and pathological study in Tokyo Metropolitan Bokutoh Hospital. Ten patients underwent hepatectomy for metastases from gastric cancer out of 1807 patients with gastric cancer between 1981 and 1998.
  
  
  METHODS
  Clinical investigation and histopathological examination of resected specimen.
  
  
  METHODS
  Survival, recurrence, liver metastases and lymph node metastases.
  
  
  RESULTS
  The 1-, 3-, and 5-year survival rates of these ten patients were 50%, 30%, 20%, respectively. The median survival time was 25 months, and two patients survived longer than five years. The survival time tended to be longer, but not to a significant extent, in patients with no lymph nodal involvement at the primary site (P = 0.067).
  
  
  CONCLUSIONS
  Even though it is rare, a survival time of 5-years can be achieved by resection of gastric cancer metastatic to the liver. These results suggest that a patient with liver metastasis from gastric cancer has a greater chance of surviving long-term if there is no lymph node metastasis at the primary site.
authors.affiliation: Department of Surgery, Tokyo Bokutoh Metropolitan Hospital, Tokyo, Japan. saiura-tky@umin.ac.jp
authors.forename: Akio
authors.initials: A
authors.lastname: Saiura
authors.forename: Nobutaka
authors.initials: N
authors.lastname: Umekita
authors.forename: Satoru
authors.initials: S
authors.lastname: Inoue
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Maeshiro
authors.forename: Sachio
authors.initials: S
authors.lastname: Miyamoto
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Matsui
authors.forename: Masahiro
authors.initials: M
authors.lastname: Asakage
authors.forename: Masatsugu
authors.initials: M
authors.lastname: Kitamura
mesh_terms: D000328:Adult; D000368:Aged; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D005743:Gastrectomy; D006498:Hepatectomy; D017052:Hospital Mortality; D006801:Humans; D008099:Liver / Q000473:pathology; D008113:Liver Neoplasms / Q000401:mortality / Q000473:pathology / Q000556:secondary* / Q000601:surgery; D008197:Lymph Node Excision; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D005472:Fluorouracil